Checkpoint Therapeutics Reports Quarterly Earnings Results

Checkpoint Therapeutics (NASDAQ:CKPT) released its quarterly earnings on Friday, reporting earnings per share (EPS) of ($0.69). This result was significantly below analysts' expectations, which had projected an EPS of ($0.22), indicating a miss by $0.47, according to reports from Zacks.

Checkpoint Therapeutics Stock Performance

During trading on Friday, CKPT's stock saw a slight increase of 0.2%, closing at $4.04. A total of 522,554 shares were traded, which is lower than its average trading volume of 1,124,079 shares. The company's market capitalization stands at approximately $197.29 million, with a price-to-earnings ratio of -2.20 and a beta of 1.41. Over the past year, the stock has experienced a low of $1.38 and a high of $4.50. Currently, its 50-day moving average is $3.32 while the 200-day moving average is $3.25.

Analysts' Opinions on CKPT

Recently, Checkpoint Therapeutics has been the focus of several analysts. On March 11th, HC Wainwright reaffirmed a "neutral" rating for CKPT and set a price target of $4.10 on the stock. On March 10th, Lake Street Capital issued a "hold" rating, reducing their price target from $7.00 to $4.10. Furthermore, D. Boral Capital also reiterated a "buy" rating, lowering their price target from $9.00 to $4.80, also on March 10th.

Insider Trades in Checkpoint Therapeutics

In insider trading news, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics on February 6th, at an average price of $3.67, totaling approximately $271,983.70. Post-sale, he holds 1,458,644 shares, valued at about $5,353,223.48, which is a 4.84% reduction in his stock ownership. This sale was disclosed with the Securities & Exchange Commission. Additionally, CEO James F. Oliviero III sold 9,233 shares on February 7th, at an average price of $3.41, amounting to a total of roughly $31,484.53. After this transaction, he owns about 3,785,350 shares, valued at approximately $12,908,043.50, reflecting a 0.24% decrease in his ownership. Throughout the last three months, insiders have traded a total of 93,674 shares worth $336,011, and insiders currently own 2.10% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology firm focused on developing and commercializing innovative treatments for solid tumor cancers, both domestically and abroad. The company's lead candidate is Cosibelimab, currently in Phase 1 clinical trials aimed at treating patients with specific recurrent or metastatic cancers. Another product candidate, CK-302, is in preclinical development for various hematological malignancies and solid tumors.

Earnings, Stock, Analysis